StemCell Institute
TSE:7096
StemCell Institute
TSE:7096
Price:
784
JPY
1.03%
Market Closed
Market Cap:
¥8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
StemCell Institute
TSE:7096
|
JP |
|
H
|
HKScan Oyj
OMXH:HKSAV
|
FI |
|
Halma PLC
LSE:HLMA
|
UK |
|
China Lilang Ltd
HKEX:1234
|
CN |
Income Statement
Earnings Waterfall
StemCell Institute
StemCell Institute
Income Statement
StemCell Institute
StemCell Institute
Currency: JPY
| Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Revenue |
1 410
N/A
|
1 834
+30%
|
2 275
+24%
|
1 662
-27%
|
1 782
+7%
|
1 851
+4%
|
1 953
+6%
|
2 044
+5%
|
2 091
+2%
|
2 176
+4%
|
2 268
+4%
|
2 397
+6%
|
2 481
+4%
|
2 583
+4%
|
2 641
+2%
|
2 637
0%
|
2 679
+2%
|
2 701
+1%
|
3 421
+27%
|
3 484
+2%
|
|
| Gross Profit | |||||||||||||||||||||
| Cost of Revenue |
(485)
|
(650)
|
(812)
|
(616)
|
(671)
|
(686)
|
(725)
|
(745)
|
(755)
|
(780)
|
(805)
|
(857)
|
(905)
|
(939)
|
(966)
|
(977)
|
(987)
|
(1 017)
|
(1 307)
|
(1 336)
|
|
| Gross Profit |
924
N/A
|
1 184
+28%
|
1 463
+24%
|
1 045
-29%
|
1 111
+6%
|
1 164
+5%
|
1 228
+5%
|
1 300
+6%
|
1 336
+3%
|
1 395
+4%
|
1 463
+5%
|
1 540
+5%
|
1 576
+2%
|
1 644
+4%
|
1 675
+2%
|
1 660
-1%
|
1 692
+2%
|
1 684
0%
|
2 114
+26%
|
2 148
+2%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(837)
|
(1 048)
|
(1 266)
|
(881)
|
(884)
|
(914)
|
(947)
|
(980)
|
(1 038)
|
(1 083)
|
(1 114)
|
(1 148)
|
(1 162)
|
(1 195)
|
(1 219)
|
(1 243)
|
(1 274)
|
(1 324)
|
(1 758)
|
(1 804)
|
|
| Selling, General & Administrative |
(822)
|
(1 047)
|
(1 265)
|
(881)
|
(865)
|
(914)
|
(947)
|
(980)
|
(1 016)
|
(1 083)
|
(1 114)
|
(1 148)
|
(1 132)
|
(1 195)
|
(1 219)
|
(1 243)
|
(1 233)
|
(1 324)
|
(1 758)
|
(1 804)
|
|
| Research & Development |
(8)
|
0
|
0
|
0
|
(10)
|
0
|
0
|
0
|
(9)
|
0
|
0
|
0
|
(11)
|
0
|
0
|
0
|
(19)
|
0
|
0
|
0
|
|
| Depreciation & Amortization |
(8)
|
0
|
0
|
0
|
(9)
|
0
|
0
|
0
|
(13)
|
0
|
0
|
0
|
(19)
|
0
|
0
|
0
|
(23)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
0
|
|
| Operating Income |
87
N/A
|
136
+57%
|
196
+44%
|
164
-16%
|
227
+38%
|
250
+10%
|
280
+12%
|
320
+14%
|
298
-7%
|
312
+5%
|
349
+12%
|
392
+12%
|
414
+5%
|
449
+8%
|
457
+2%
|
416
-9%
|
419
+1%
|
360
-14%
|
356
-1%
|
343
-4%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
2
|
24
|
25
|
25
|
26
|
141
|
142
|
144
|
146
|
10
|
15
|
16
|
|
| Non-Reccuring Items |
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(21)
|
(20)
|
(20)
|
(20)
|
2
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Total Other Income |
5
|
(7)
|
(10)
|
(15)
|
(15)
|
(2)
|
1
|
1
|
1
|
3
|
0
|
0
|
(0)
|
(2)
|
3
|
3
|
1
|
1
|
(3)
|
(2)
|
|
| Pre-Tax Income |
91
N/A
|
129
+41%
|
186
+44%
|
150
-20%
|
213
+42%
|
249
+17%
|
282
+13%
|
322
+14%
|
279
-13%
|
319
+15%
|
354
+11%
|
398
+12%
|
441
+11%
|
588
+33%
|
602
+2%
|
563
-7%
|
566
+1%
|
371
-34%
|
369
-1%
|
358
-3%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
(29)
|
(43)
|
(63)
|
(51)
|
(79)
|
(88)
|
(100)
|
(114)
|
(81)
|
(96)
|
(107)
|
(117)
|
(130)
|
(175)
|
(179)
|
(167)
|
(180)
|
(121)
|
(127)
|
(125)
|
|
| Income from Continuing Operations |
62
|
86
|
123
|
99
|
134
|
161
|
183
|
208
|
198
|
223
|
248
|
281
|
311
|
414
|
423
|
396
|
386
|
251
|
242
|
233
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| Net Income (Common) |
62
N/A
|
86
+38%
|
123
+44%
|
99
-20%
|
134
+35%
|
161
+20%
|
183
+14%
|
208
+14%
|
198
-5%
|
223
+13%
|
248
+11%
|
281
+13%
|
311
+11%
|
414
+33%
|
423
+2%
|
396
-6%
|
386
-3%
|
251
-35%
|
242
-3%
|
236
-3%
|
|
| EPS (Diluted) |
6.09
N/A
|
16.78
+176%
|
12.03
-28%
|
9.67
-20%
|
13.05
+35%
|
15.69
+20%
|
17.85
+14%
|
20.34
+14%
|
19.33
-5%
|
21.77
+13%
|
24.17
+11%
|
27.4
+13%
|
30.35
+11%
|
40.37
+33%
|
41.3
+2%
|
38.64
-6%
|
37.67
-3%
|
24.65
-35%
|
23.87
-3%
|
23.39
-2%
|
|
Switch to:
Switch to:
See Also
Discover More
